medigraphic.com

2022, Número 2

<< Anterior Siguiente >>

Rev Cuba Endoc 2022; 33 (2)


Mitos y realidades sobre la obesidad en el síndrome de ovario poliquístico

Monteagudo PG, Rodríguez PB, Ovies CG, Gómez AM, Álvarez ÁA, Cabrera GM

Idioma: Español
Referencias bibliográficas: 100
Paginas:
Archivo PDF: 277.62 Kb.


RESUMEN

Introducción: La asociación entre la obesidad y el síndrome de ovario poliquístico es importante porque amplifica los trastornos metabólicos, reproductivos, psicológicos o de la calidad de vida. Sin embargo, es común que se sobrevalore o se emplee como criterio diagnóstico, lo que denota una definición no clara de esta relación.
Objetivo: Analizar lo que, en opinión de los autores, pudieran ser “mitos” sobre la obesidad en el síndrome de ovario poliquístico y su coherencia con la evidencia disponible.
Métodos: Se realizó una revisión del estado del arte en este tema. Se localizaron 230 artículos en las bases PubMed, Medline, Scielo y Google Académico, y se contrastó con los criterios propios.
Conclusiones: Algunas creencias generalizadas sobre la obesidad en el síndrome de ovario poliquístico, aunque tienen cierto grado de certidumbre, se malinterpretan o magnifican, por lo que pueden considerarse “mitos”. Entender que las mujeres con síndrome de ovario poliquístico pueden no tener obesidad y, aún así, tener adiposidad abdominal y los efectos que de ella derivan, no niega la evidencia indiscutible de que la obesidad, si está presente, agrava el síndrome. Polemizar sobre el tema pretende contribuir a que se diagnostique el síndrome no solo en mujeres con obesidad y que se considere factor de riesgo para la obesidad. Debe entenderse que la obesidad asociada al síndrome puede revertirse y que se pueden incorporar estilos de vida saludable y un control del peso corporal como pilares del tratamiento en todas las mujeres que padezcan este.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618-37. DOI: https://doi.org/10.1093/humupd/dms0301.

  2. Jena D, Choudhury AK, Mangaraj S, Singh M, Mohanty BK, Baliarsinha AK. Study of Visceral and Subcutaneous Abdominal Fat Thickness and Its Correlation with Cardiometabolic Risk Factors and Hormonal Parameters in Polycystic Ovary Syndrome. Indian J Endocrinol Metab. 2018;22(3):321-7. DOI: https://doi.org/10.4103/ijem.IJEM_646_172.

  3. Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev. 2013;14(2):95-109. DOI: https://doi.org/10.1111/j.1467-789X.2012.01053.x3.

  4. Sidra S, Tariq MH, Farrukh MJ, Mohsin M. Evaluation of clinical manifestations, health risks, and quality of life among women with polycystic ovary syndrome. PLoS One. 2019;14(10):e0223329. DOI: https://doi.org/10.1371/journal.pone.02233294.

  5. Cesta CE, Mansson M, Palm C, Lichtenstein P, Iliadou AN, Landén M. Polycystic ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a nationwide Swedish cohort. Psychoneuroendocrinology. 2016;73:196-203. DOI: https://doi.org/10.1016/j.psyneuen.2016.08.0055.

  6. Pasquali R. Metabolic Syndrome in Polycystic Ovary Syndrome. Front Horm Res. 2018;49:114-30. DOI: https://doi.org/10.1159/0004859956.

  7. Pasquali R, Diamanti-Kandarakis E, Gambineri A: Management of endocrine disease: secondary polycystic ovary syndrome: theoretical and practical aspects. Eur J Endocrinol. 2016;175(4):R157-69. DOI: https://doi.org/10.1530/EJE-16-03747.

  8. Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935 [acceso: 27/12/2021];29:181-91. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S00029378153064268.

  9. Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2019;92:108-20. DOI: https://doi.org/10.1016/j.metabol.2018.11.0029.

  10. Dumesic DA, Hoyos LR, Chazenbalk GD, Naik R, Padmanabhan V, Abbott DH. Mechanisms of intergenerational transmission of polycystic ovary syndrome. Reproduction. 2020;159(1):R1-R13. DOI: https://doi.org/10.1530/REP-19-019710.

  11. Day F, Karaderi T, Jones M, Meun C, He C, Drong A, et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 2018;14(12):e1007813. DOI: https://doi.org/10.1371/journal.pgen.100781311.

  12. Douma Z, Lautier C, Haydar S, Mahjoub T, Grigorescu F. Portability of GWAS results between ethnic populations: genetic markers for polycystic ovary syndrome (PCOS) in mediterranean area. Acta Endocrinol (Buchar). 2019;15(3):364-71. DOI: https://doi.org/10.4183/aeb.2019.36412.

  13. Goodarzi MO, Malecki MT, Strauss JF. Meta-analysis of association of FTO genetic variation with PCOS must account for obesity. Genomics. 2020;112(3):2164-5. DOI: https://doi.org/10.1016/j.ygeno.2019.12.01013.

  14. Batarfi A, Filimban N, Bajouh O, Chaudhary A, Bakhashab S. MC4R variants rs12970134 and rs17782313 are associated with obese polycystic ovary syndrome patients in the Western region of Saudi Arabia. BMC Med Genet. 2019;20:144. DOI: https://doi.org/10.1186/s12881-019-087614.

  15. Li T, Wu K, You L, Xing X, Wang P, Cui L, et al. Common variant rs9939609 in gene FTO confers risk to polycystic ovary syndrome. PLoS One. 2013;8(7):e66250. DOI: https://doi.org/10.1371/journal.pone.006625015.

  16. Liu AL, Xie HJ, Xie HY, Liu J, Yin J, Hu JS, et al. Association between fat mass and obesity associated (FTO) gene rs9939609 A/T polymorphism and polycystic ovary syndrome: a systematic review and meta-analysis. BMC Med Genet. 2017;18(1):89. DOI: https://doi.org/10.1186/s12881-017-0452-116.

  17. Ramos RB, Spritzer PM. FTO gene variants are not associated with polycystic ovary syndrome in women from Southern Brazil. Gene. 2015;560(1):25-9. DOI: https://doi.org/10.1016/j.gene.2015.01.01217.

  18. Branavan U, Wijesundera S, Chandrasekaran V, Arambepola C, Wijeyaratne C. In depth analysis of the association of FTO SNP (rs9939609) with the expression of classical phenotype of PCOS: A Sri Lankan study. BMC Med Genet. 2020;21(1):30. DOI: https://doi.org/10.1186/s12881-020-0961-118.

  19. Barber TM, Bennett AJ, Groves CJ, Sovio U, Ruokonen A, Martikainen H, et al. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia. 2008;51(7):1153-8. DOI: https://doi.org/10.1007/s00125-008-1028-619.

  20. Liu Y, Chen Y. Fat Mass and Obesity Associated Gene Polymorphism and the Risk of Polycystic Ovary Syndrome: A Meta-analysis. Iran J Public Health. 2017 [acceso: 27/12/2021];46(1):4-11. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401934/20.

  21. Chazenbalk G, Chen Y, Heneidi S, Lee J, Pall M, Chen Y, et al. Abnormal expression of genes involved in inflammation, lipid metabolism, and Wnt signaling in the adipose tissue of polycystic ovary syndrome. J Clin Endocrinol Metab. 2012;97:E765-70. DOI: https://doi.org/10.1210/jc.2011-237721.

  22. Nambiar V, Vijesh V, Lakshmanan P, Sukumaran S, Suganthi R. Association of adiponectin and resistin gene polymorphisms in South Indian women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016;200:82-8. DOI: https://doi.org/10.1016/j.ejogrb.2016.02.03122.

  23. Concha CF, Sir PT, Recabarren SE, Pérez BF. Epigenética del síndrome de ovario poliquístico. Rev Med Chil. 2017;145(7):907-15. DOI: https://doi.org/10.4067/s0034-9887201700070090723.

  24. Mumm H, Kamper-Jørgensen M, Nybo Andersen AM, Glintborg D, Andersen M. Birth weight and polycystic ovary syndrome in adult life: a register-based study on 523,757 Danish women born 1973-1991. Fertil Steril. 2013;99(3):777-82. DOI: https://doi.org/10.1016/j.fertnstert.2012.11.00424.

  25. Kempegowda P, Melson E, Manolopoulos K, Arlt W, O'Reilly M. Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020;11:2042018820934319. DOI: https://doi.org/10.1177/204201882093431925.

  26. Risal S, Pei Y, Lu H, Manti M, Fornes R, Pui HP, et al. Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome. Nat Med. 2019;25(12):1894-1904. DOI: https://doi.org/10.1038/s41591-019-0666-126.

  27. Boyle JA, Cunningham J, Norman RJ, Dunbar T, O'Dea K. Polycystic ovary syndrome and metabolic syndrome in Indigenous Australian women. Intern Med J. 2015;45(12):1247-54. DOI: https://doi.org/10.1111/imj.1291027.

  28. Hu X, Wang J, Dong W, Fang Q, Hu L, Liu C. A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy. Epilepsy Res. 2011;97(1-2):73-82. DOI: https://doi.org/10.1016/j.eplepsyres.2011.07.00628.

  29. Carbone L, Davis B, Fei S, White A, Nevonen K, Takahashi D, et al. Synergistic Effects of Hyperandrogenemia and Obesogenic Western-style Diet on Transcription and DNA Methylation in Visceral Adipose Tissue of Nonhuman Primates. Sci Rep. 2019;9:19232. DOI: https://doi.org/10.1038/s41598-019-55291-829.

  30. Volk K, Pogrebna V, Roberts J, Zachry J, Blythe S, Toporikova N. High-Fat, High-Sugar Diet Disrupts the Preovulatory Hormone Surge and Induces Cystic Ovaries in Cycling Female Rats. J Endocr Soc. 2017;1:1488-505. DOI: https://doi.org/10.1210/js.2017-0030530.

  31. Saad M, Santos A, Prada P. Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. Physiol. 2016;31:283-93. DOI: https://doi.org/10.1152/physiol.00041.201531.

  32. Baldani D, Skrgatic L, Kasum M, Zlopasa G, Oguic S, Herman M. Altered leptin, adiponectin, resistin and ghrelin secretion may represent an intrinsic polycystic ovary syndrome abnormality. Gynecol Endocrinol. 2019;35:401-5. DOI: https://doi.org/10.1080/09513590.2018.153409632.

  33. Elboghdady A, Abd A, Mohamed E, Saeed A. Copeptin and Obesta tin Levels in Polycystic Ovary Women and their Relation to Obesity, Insulin Metabolism and Cardiovascular Diseases. AIMJ. 2020;1(4):44-9. DOI: https://doi.org/10.21608/aimj.2020.27820.119733.

  34. O'Reilly MW, Kempegowda P, Walsh M, Taylor AE, Manolopoulos KN, Allwood JW, et al. AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017;102(9):3327-39. DOI: https://doi.org/10.1210/jc.2017-0094734.

  35. Anik Ilhan G, Yildizhan B, Pekin T. The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome. Gynecol Endocrinol. 2019;35(3):233-6. DOI: https://doi.org/10.1080/09513590.2018.151979435.

  36. Kempegowda P, Melson E, Manolopoulos K, Arlt W, O'Reilly M. Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020;11:2042018820934319. DOI: https://doi.org/10.1177/204201882093431936.

  37. Schiffer L, Arlt W, O'Reilly M. Understanding the Role of Androgen Action in Female Adipose Tissue. Front Horm Res. 2019;53:33-49. DOI: https://doi.org/10.1159/00049490137.

  38. Zeng X, Xie Y, Liu Y, Long S, Mo Z. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214-21. DOI: https://doi.org/10.1016/j.cca.2019.11.00338.

  39. Dimitriadis G, Kyrou I, Randeva H. Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines. Curr Pharm Des. 2016;22:5535-46. DOI: https://doi.org/10.2174/138161282266616072610313339.

  40. Dewailly D, Robin G, Peigne M, Decanter C, Pigny P, Catteau-Jonard S. Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum Reprod Update. 2016;22:709-24. DOI: https://doi.org/10.1093/humupd/dmw02740.

  41. Baldani DP, Skrgatic L, Kasum M, Zlopasa G, Kralik Oguic S, Herman M. Altered leptin, adiponectin, resistin and ghrelin secretion may represent an intrinsic polycystic ovary syndrome abnormality. Gynecol Endocrinol. 2019;35(5):401-5. DOI: https://doi.org/10.1080/09513590.2018.153409641.

  42. Glintborg D, Andersen M, Hagen C, Frystyk J, Hulstrøm V, Flyvbjerg A, et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol. 2006;155(2):337-45. DOI: https://doi.org/10.1530/eje.1.0220742.

  43. Barber T, Hanson P, Weickert M, Franks S. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042. DOI: https://doi.org/10.1177/117955811987404243.

  44. Idicula S, Gawde U, Bhaye S, Pokar K, Bader G. Meta-analysis of gene expression profiles of lean and obese PCOS to identify differentially regulated pathways and risk of comorbidities. Comput Struct Biotechnol J. 2020;18:1735-45. DOI: https://doi.org/10.1016/j.csbj.2020.06.02344.

  45. Hansen S, Svendsen P, Jeppesen J, Hoeg L, Andersen N, Kristensen J, et al. Molecular mechanisms in skeletal muscle underlying insulin resistance in women who are lean with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104:1841-54. DOI: https://doi.org/10.1210/jc.2018-0177145.

  46. Tran L, Langlais PR, Hoffman N, Roust L, Katsanos CS. Mitochondrial ATP synthase ß-subunit production rate and ATP synthase specific activity are reduced in skeletal muscle of humans with obesity. Exp Physiol. 2019;104(1):126-35. DOI: https://doi.org/10.1113/EP08727846.

  47. Handy DE, Loscalzo J. Redox regulation of mitochondrial function. Antioxid Redox Signal. 2012;16(11):1323-67. DOI: https://doi.org/10.1089/ars.2011.412347.

  48. Lin K, Sun X, Wang X, Wang H, Chen X. Circulating Adipokine Levels in Nonobese Women With Polycystic Ovary Syndrome and in Nonobese Control Women: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021;11:537809. DOI: https://doi.org/10.3389/fendo.2020.53780948.

  49. Liou TH, Yang JH, Hsieh CH, Lee CY, Hsu CS, Hsu MI. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil Steril. 2009;92(6):1960-5. DOI: https://doi.org/10.1016/j.fertnstert.2008.09.00349.

  50. Manneras L, Leonhardt H, Kullberg J, Jennische E, Odén A, Holm G, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011;96:304-11. DOI: https://doi.org/10.1210/jc.2010-129050.

  51. Fisch SC, Nikou AF, Wright EA, Phan JD, Leung KL, Grogan TR, et al. Precocious subcutaneous abdominal stem cell development to adipocytes in normal-weight women with polycystic ovary syndrome. Fertil Steril. 2018;110(7):1367-76. DOI: https://doi.org/10.1016/j.fertnstert.2018.08.04251.

  52. Dumesic D, Akopians A, Madrigal V, Ramirez E, Margolis D, Sarma MK, et al. Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women. J Clin Endocrinol Metab. 2016;101:4178-88. DOI: https://doi.org/10.1210/jc.2016-258652.

  53. Brennan KM, Kroener LL, Chazenbalk GD, Dumesic DA. Polycystic Ovary Syndrome: Impact of Lipotoxicity on Metabolic and Reproductive Health. Obstet Gynecol Surv. 2019;74(4):223-31. DOI: https://doi.org/10.1097/OGX.000000000000066153.

  54. Lin K, Sun X, Wang X, Wang H, Chen X. Circulating Adipokine Levels in Nonobese Women with Polycystic Ovary Syndrome and in Nonobese Control Women: A Systematic Review and Meta-Analysis. Front Endocrinol. 2021;11:537809. DOI: https://doi.org/10.3389/fendo.2020.53780954.

  55. Cree-Green M, Newcomer BR, Coe G, Newnes L, Baumgartner A, Brown MS, et al. Peripheral insulin resistance in obese girls with hyperandrogenism is related to oxidative phosphorylation and elevated serum free fatty acids. Am J Physiol Endocrinol Metab. 2015;308(9):E726-33. DOI: https://doi.org/10.1152/ajpendo.00619.201455.

  56. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008;10:e3. DOI: https://doi.org/10.1017/S146239940800059856.

  57. Behboudi-Gandevani S, Ramezani Tehrani F, Bidhendi Yarandi R, Noroozzadeh M, Hedayati M, Azizi F. The association between polycystic ovary syndrome, obesity, and the serum concentration of adipokines. J Endocrinol Invest. 2017;40(8):859-66. DOI: https://doi.org/10.1007/s40618-017-0650-x.57.

  58. Benrick A, Chanclón B, Micallef P, Wu Y, Hadi L, Shelton JM, et al. Adiponectin protects against development of metabolic disturbances in a PCOS mouse model. Proc Natl Acad Sci U S A. 2017;114(34):E7187-E96. DOI: https://doi.org/10.1073/pnas.170885411458.

  59. Obirikorang C, Owiredu WKBA, Adu-Afram S, Acheampong E, Asamoah EA, Antwi-Boasiakoh EK, et al. Assessing the variability and predictability of adipokines (adiponectin, leptin, resistin and their ratios) in non-obese and obese women with anovulatory polycystic ovary syndrome. BMC Res Notes. 2019;12(1):513. DOI: https://doi.org/10.1186/s13104-019-4546-z59.

  60. Li S, Huang X, Zhong H, Peng Q, Chen S, Xie Y, et al. Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis. Tumour Biol. 2014;35(5):3961-73. DOI: https://doi.org/10.1007/s13277-013-1595-060.

  61. Abbasi F, Chu JW, Lamendola C, McLaughlin T, Hayden J, Reaven GM, et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes. 2004;53(3):585-90. DOI: https://doi.org/10.2337/diabetes.53.3.58561.

  62. Flier JS, Maratos-Flier E. Leptin's Physiologic Role: Does the Emperor of Energy Balance Have No Clothes? Cell Metab. 2017;26(1):24-6. DOI: https://doi.org/10.1016/j.cmet.2017.05.01362.

  63. Ozgokce C, Elci E, Yildizhan R. C-Reactive Protein, Fibrinogen, Leptin, and Adiponectin Levels in Women with Polycystic Ovary Syndrome. J Obstet Gynaecol India. 2020;70(6):490-6. DOI: https://doi.org/10.1007/s13224-020-01331-763.

  64. Zheng SH, Du DF, Li XL. Leptin Levels in Women With Polycystic Ovary Syndrome: A Systematic Review and a Meta-Analysis. Reprod Sci. 2017;24(5):656-70. DOI: https://doi.org/10.1177/193371911667026564.

  65. Remsberg KE, Talbott EO, Zborowski JV, Evans RW, McHugh-Pemu K. Evidence for competing effects of body mass, hyperinsulinemia, insulin resistance, and androgens on leptin levels among lean, overweight, and obese women with polycystic ovary syndrome. Fertil Steril. 2002;78(3):479-86. DOI: https://doi.org/10.1016/s0015-0282(02)03303-465.

  66. Veldhuis JD, Pincus SM, Garcia-Rudaz MC, Ropelato MG, Escobar ME, Barontini M. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001;86(8):3772-8. DOI: https://doi.org/10.1210/jcem.86.8.777566.

  67. Abdalla MMI. Salivary resistin level and its association with insulin resistance in obese individuals. World J Diabetes. 2021;15;12(9):1507-17. DOI: https://doi.org/10.4239/wjd.v12.i9.150767.

  68. Seow KM, Juan CC, Wu LY, Hsu YP, Yang WM, Tsai YL, Hwang JL, Ho LT. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod. 2004;19(1):48-53. DOI: https://doi.org/10.1093/humrep/deh01068.

  69. Sun Y, Wu Z, Wei L, Liu C, Zhu S, Tang S. High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis. Gynecol Endocrinol. 2015;31(10):808-14. DOI: 10.3109/09513590.2015.105614069.

  70. Moustafa S, Al-Hakeim H. The impact of serum visfatin, and resistin levels on insulin resistance in patients with polycystic ovary syndrome. ZJMS. 30Apr.2020 [acceso: 27/12/2021];24(1):80-8. Disponible en: https://zjms.hmu.edu.krd/index.php/zjms/article/view/71370.

  71. Abdul-Maksoud RS, Zidan HE, Saleh HS, Amer SA. Visfatin and SREBP-1c mRNA Expressions and Serum Levels Among Egyptian Women with Polycystic Ovary Syndrome. Genet Test Mol Biomarkers. 2020;24(7):409-19. DOI: https://doi.org/https://doi.org/10.1089/gtmb.2019.019271.

  72. Olszanecka M, Madej P, Zdun D, Bozentowicz M, Sikora J, Chudek J, et al. Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol.2012;162:55-61. DOI: https://doi.org/10.1016/j.ejogrb.2012.01.02672.

  73. Garza-Garza MA, Delgadillo-Guzmán D. Involvement of TNF-alpha in the polycystic ovary syndrome. Ginecol Obstet Mex. 2020 [acceso: 27/12/2021];88(06):385-93. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=9356373.

  74. Gao L, Gu Y, Yin X. High Serum Tumor Necrosis Factor-Alpha Levels in Women with Polycystic Ovary Syndrome: A Meta-Analysis. PLoS One. 2016;11:e0164021. DOI: https://doi.org/10.1371/journal.pone.016402174.

  75. Escobare H, Luquez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95:1048-58.e1-2. doi: https://doi.org/10.1016/j.fertnstert.2010.11.03675.

  76. Puder J, Varga S, Nusbaumer C, Zulewski H, Bilz S, Müller B, Keller U. Women with polycystic ovary syndrome are sensitive to the TNF-alpha-lowering effect of glucose-induced hyperinsulinaemia. Eur J Clin Invest. 2006;36:883-9. DOI: https://doi.org/10.1111/j.1365-2362.2006.01734.x76. . [ Links ]

  77. Cardoso N, Ribeiro V, Dutra S, Ferriani R, Gastaldi A, Araújo J, et al. Polycystic ovary syndrome associated with increased adiposity interferes with serum levels of TNF-alpha and IL-6 differently from leptin and adiponectin. Arch Endocrinol Metab. 2020;64:4-10. DOI: https://doi.org/10.20945/2359-399700000019777.

  78. Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;3(3):CD007506. DOI: https://doi.org/10.1002/14651858.CD007506.pub478.

  79. Jeanes YM, Reeves S. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges. Nutr Res Rev. 2017;30(1):97-105. DOI: https://doi.org/10.1017/S095442241600028779.

  80. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013;28(3):777-84. DOI: https://doi.org/10.1093/humrep/des46380.

  81. Mayer SB, Evans WS, Nestler JE. Polycystic ovary syndrome and insulin: our understanding in the past, present and future. Womens Health (Lond). 2015;11(2):137-49. DOI: https://doi.org/10.2217/whe.14.7381.

  82. Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, Joham AE, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2019;20(2):339-52. DOI: https://doi.org/10.1111/obr.1276282.

  83. Dumesic DA, Phan JD, Leung KL, Grogan TR, Ding X, Li X, et al. Adipose Insulin Resistance in Normal-Weight Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019;104(6):2171-83. DOI: https://doi.org/10.1210/jc.2018-0208683.

  84. Talmor A, Dunphy B. Female obesity and infertility. Best Pract Res Clin Obstet Gynaecol. 2015;29(4):498-506. DOI: https://doi.org/10.1016/j.bpobgyn.2014.10.01484.

  85. Koivuaho E, Laru J, Ojaniemi M, Puukka K, Kettunen J, Tapanainen J, et al. Age at adiposity rebound in childhood is associated with PCOS diagnosis and obesity in adulthood-longitudinal analysis of BMI data from birth to age 46 in cases of PCOS. Int J Obes. 2019;43:1370-79. DOI: https://doi.org/10.1038/s41366-019-0318-z85.

  86. Cheng XB, Wen JP, Yang J, Yang Y, Ning G, Li XY. GnRH secretion is inhibited by adiponectin through activation of AMP-activated protein kinase and extracellular signal-regulated kinase. Endocrine. 2011;39(1):6-12. DOI: https://doi.org/10.1007/s12020-010-9375-886.

  87. Brower MA, Hai Y, Jones MR, Guo X, Chen YI, Rotter JI, et al. Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome. Hum Reprod. 2019;34(1):127-36. DOI: 10.1093/humrep/dey34387.

  88. Broughton DE, Moley KH. Obesity and female infertility: potential mediators of obesity's impact. Fertil Steril. 2017;107(4):840-7. DOI: https://doi.org/10.1016/j.fertnstert.2017.01.01788. . [ Links ]

  89. Gonzalez MB, Lane M, Knight EJ, Robker RL. Inflammatory markers in human follicular fluid correlate with lipid levels and Body Mass Index. J Reprod Immunol. 2018;130:25-9. DOI: https://doi.org/10.1016/j.jri.2018.08.00589. . [ Links ]

  90. Chabrolle C, Tosca L, Ramé C, Lecomte P, Royère D, Dupont J. Adiponectin increases insulin-like growth factor I-induced progesterone and estradiol secretion in human granulosa cells. Fertil Steril. 2009;92(6):1988-96. DOI https://doi.org/10.1016/j.fertnstert.2008.09.00890. . [ Links ]

  91. Silvestrim RL, Bos-Mikich A, Roos ML, Frantz N. The Effects of Overweight and Obesity on Assisted Reproduction Technology Outcomes. JBRA. 2019;23(3):281-6. DOI: https://doi.org/10.5935/1518-0557.2019000591.

  92. Wang H, Cheng Q, Li X, Hu F, Han L, Zhang H, et al. Loss of TIGAR Induces Oxidative Stress and Meiotic Defects in Oocytes from Obese Mice. Mol Cell Proteomics. 2018;17(7):1354-64. DOI: https://doi.org/10.1074/mcp.RA118.00062092. . [ Links ]

  93. Wise LA, Rothman KJ, Mikkelsen EM, Sørensen HT, Riis A, Hatch EE. An internet-based prospective study of body size and time-to-pregnancy. Hum Reprod. 2010;25(1):253-64. DOI: https://doi.org/10.1093/humrep/dep36093. . [ Links ]

  94. Bahri M, Joham A, Boyle J, Piltonen T, Silagy M, Arora C, et al. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-A systematic review, meta-analysis, and meta-regression. Obes Rev. 2019;20:659-74. DOI: https://doi.org/10.1111/obr.1282994. . [ Links ]

  95. Ozegowska K, Korman M, Szmyt A, Pawelczyk L. Heterogeneity of Endocrinologic and Metabolic Parameters in Reproductive Age Polycystic Ovary Syndrome (PCOS) Women Concerning the Severity of Hyperandrogenemia-A New Insight on Syndrome Pathogenesis. Int J Environ Res Public Health. 2020;17:9291. DOI: https://doi.org/10.3390/ijerph1724929195.

  96. Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med. 2012;30(6):496-506. doi: https://doi.org/10.1055/s-0032-132887896. . [ Links ]

  97. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019 Mar;92:6-10. DOI: https://doi.org/10.1016/j.metabol.2018.09.00597.

  98. Carmina E, Napoli N, Longo R, Rini G, Lobo R. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154:141-5. DOI: https://doi.org/10.1530/eje.1.0205898.

  99. Monteagudo Peña G, González Suárez R, Gómez Alzugaray M, Ovies Carballo G, Menocal Alayón A, Rodríguez Martínez K, et al. Resistencia a la insulina en mujeres con Síndrome de Ovario Poliquístico. Rev Cub Endocrinol. 2020 [acceso: 27/12/2021];30(2):e179. Disponible en: http://www.revendocrinologia.sld.cu/index.php/endocrinologia/article/view/17999.

  100. Lizneva D, Kirubakaran R, Mykhalchenko K, Suturina L, Chernukha G, Diamond M, et al. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril. 2016;106:1510-20.e2. DOI: https://doi.org/10.1016/j.fertnstert.2016.07.1121100.




2020     |     www.medigraphic.com